161 related articles for article (PubMed ID: 34589108)
1. A Plant-Produced Virus-Like Particle Displaying Envelope Protein Domain III Elicits an Immune Response Against West Nile Virus in Mice.
Stander J; Chabeda A; Rybicki EP; Meyers AE
Front Plant Sci; 2021; 12():738619. PubMed ID: 34589108
[TBL] [Abstract][Full Text] [Related]
2. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
[TBL] [Abstract][Full Text] [Related]
3. Plant-Produced Antigen Displaying Virus-Like Particles Evokes Potent Antibody Responses against West Nile Virus in Mice.
He J; Lai H; Esqueda A; Chen Q
Vaccines (Basel); 2021 Jan; 9(1):. PubMed ID: 33477363
[TBL] [Abstract][Full Text] [Related]
4. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
5. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
Chu JH; Chiang CC; Ng ML
J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
[TBL] [Abstract][Full Text] [Related]
6. Cross protection against lethal West Nile virus challenge in mice immunized with recombinant E protein domain III of Japanese encephalitis virus.
Li SH; Li XF; Zhao H; Jiang T; Deng YQ; Yu XD; Zhu QY; Qin ED; Qin CF
Immunol Lett; 2011 Aug; 138(2):156-60. PubMed ID: 21515306
[TBL] [Abstract][Full Text] [Related]
7. Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein.
Cielens I; Jackevica L; Strods A; Kazaks A; Ose V; Bogans J; Pumpens P; Renhofa R
Mol Biotechnol; 2014 May; 56(5):459-69. PubMed ID: 24570176
[TBL] [Abstract][Full Text] [Related]
8. Enhanced production and immunological characterization of recombinant West Nile virus envelope domain III protein.
Tripathi NK; Karothia D; Shrivastava A; Banger S; Kumar JS
N Biotechnol; 2018 Nov; 46():7-13. PubMed ID: 29768182
[TBL] [Abstract][Full Text] [Related]
9. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
[TBL] [Abstract][Full Text] [Related]
10. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
11. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
[TBL] [Abstract][Full Text] [Related]
13. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate.
Ohtaki N; Takahashi H; Kaneko K; Gomi Y; Ishikawa T; Higashi Y; Kurata T; Sata T; Kojima A
Vaccine; 2010 Sep; 28(40):6588-96. PubMed ID: 20678586
[TBL] [Abstract][Full Text] [Related]
15. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
[TBL] [Abstract][Full Text] [Related]
16. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.
Goo L; Debbink K; Kose N; Sapparapu G; Doyle MP; Wessel AW; Richner JM; Burgomaster KE; Larman BC; Dowd KA; Diamond MS; Crowe JE; Pierson TC
Nat Microbiol; 2019 Jan; 4(1):71-77. PubMed ID: 30455471
[TBL] [Abstract][Full Text] [Related]
17. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.
Desprès P; Combredet C; Frenkiel MP; Lorin C; Brahic M; Tangy F
J Infect Dis; 2005 Jan; 191(2):207-14. PubMed ID: 15609230
[TBL] [Abstract][Full Text] [Related]
18. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
19. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
Garg H; Sedano M; Plata G; Punke EB; Joshi A
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
[TBL] [Abstract][Full Text] [Related]
20. Replication-Defective West Nile Virus with NS1 Deletion as a New Vaccine Platform for Flavivirus.
Li N; Zhang YN; Deng CL; Shi PY; Yuan ZM; Zhang B
J Virol; 2019 Sep; 93(17):. PubMed ID: 31189715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
